Influenza vaccination coverage among splenectomized patients: an Italian study on the role of active recall in the vaccination compliance

Figures & data

Table 1. Sample characteristics of surgery and timing of vaccine prophylaxis, per group (intervention/control).

Variables	Intervention group (n=46)	Control group (n=50)	Total (n=96)	Test	p-value
Type of surgery; n (%)
●elective	30 (65.2%)	29 (58.0%)	59 (61.5%)	X^2=1.2	0.579
●emergency	11 (23.9%)	17 (34.0%)	28 (29.2%)
●programmed	5 (10.9%)	4 (8.0%)	9 (9.3%)
Time from the splenectomy to the start of the immunization program (days); mean±SD (range)	14.0±17.9 (1.0 - 83.0)	14.1±21.6 (1.0 - 107.0)	14.1±19.8 (1.0 - 107.0)	z=0.8	0.399
Condition requiring surgery; n (%)
●solid neoplasia	22 (47.8%)	21 (42.0%)	43 (44.8%)	X^2=2.8	0.444
●trauma	12 (26.1%)	15 (30.0%)	27 (28.1%)
●hemolymphopathy	7 (15.2%)	12 (24.0%)	19 (19.8%)
●other	5 (10.9%)	2 (4.0%)	7 (7.3%)
Time of completion of vaccination schedule (days); mean±SD (range)	77.9±28.9 (53.0 - 176.0)	71.3±18.0 (61.0 – 160.0)	74.5±23.8 (53.0 - 176.0)	z=0.3	0.801

Figure 1. Vaccine coverage (%) of the influenza vaccine (season 2017), per group (intervention/control).

Table 2. Analysis of determinants of the influenza vaccination in the 2017 season in a multivariate regression model.

Variables	aOR	95%CI	z	p-value
Group (intervention/control)	0.4	0.1-1.3	1.5	0.132
Gender (male/female)	0.5	0.2-1.8	1.0	0.312
Age (yrs)	1.03	1.00-1.09	2.0	0.041
Condition for which splenectomy was necessary
● trauma vs. solid neoplasia	1.04	0.30-3.68	0.1	0.949
● hemolymphopathy vs. solid neoplasia	13.2	1.2-148.9	2.1	0.037
● other condition vs. solid neoplasia	0.6	0.1-4.2	0.5	0.589
Time from the start of the vaccination program to the start of the study (months)	0.97	0.95-0.99	2.2	0.030
Influenza vaccination performed in at least one previous season during hospitalization	4.14	1.02-16.8	2.0	0.047

X² = 88.2; p = 0.385; aOR, adjusted odds ratio.